Levonantradol for the treatment of chemotherapy-induced nausea and vomiting.

Abstract

Twenty patients with cancer previously unresponsive to antiemetic treatment of chemotherapy-induced nausea and vomiting were treated with the new tetrahydrocannabinoid Levonantradol. 15 patients experienced substantial relief and 10 of them preferred the drug for further courses. These observations suggest that Levonantradol can be beneficial to patients refractory to conventional antiemetic therapy.

• Authors: H H Gerhartz, T Binsack, E Hiller
• Journal: Klinische Wochenschrift (Klin Wochenschr) Vol. 61 Issue 14 Pg. 719-21 (Jul 15 1983) ISSN: 0023-2173 [Print] Germany
• PMID: 6350696 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antineoplastic Agents
• Phenanthridines
• nantradol

Topics

• Adult
• Antineoplastic Agents (adverse effects)
• Anxiety (chemically induced)
• Clinical Trials as Topic
• Dizziness (chemically induced)
• Female
• Hallucinations (chemically induced)
• Humans
• Male
• Middle Aged
• Nausea (chemically induced, drug therapy)
• Phenanthridines (adverse effects, therapeutic use)
• Stereoisomerism
• Vertigo (chemically induced)
• Vomiting (chemically induced, drug therapy)